

1 A fast and agnostic method for bacterial genome-wide  
2 association studies: bridging the gap between kmers and  
3 genetic events

4 Magali Jaillard<sup>1,2,\*†</sup> Leandro Lima<sup>2,3,†</sup> Maud Tournoud<sup>1</sup>  
5 Pierre Mahé<sup>1</sup> Alex van Belkum<sup>1</sup> Vincent Lacroix<sup>2,3</sup>  
6 Laurent Jacob<sup>2</sup>

<sup>1</sup>bioMérieux, Marcy l'Étoile, France

7 <sup>2</sup> Univ Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et  
Biologie Evolutive UMR5558 F-69622 Villeurbanne, France

8 <sup>3</sup> EPI ERABLE - Inria Grenoble, Rhône-Alpes, France

9 April 6, 2018

10 **Running title:** Fast agnostic bacterial GWAS with De Bruijn graphs

11 **Keywords:** Genome variation, Association study, De Bruijn graph, Bacterial  
12 genome, Sequences, Sequencing

---

\*corresponding author (magali.dancette@biomerieux.com)

†contribution considered equal

13

## Abstract

14

**Motivation:** Genome-wide association study (GWAS) methods applied to bacterial genomes have shown promising results for genetic marker discovery or fine-assessment of marker effect. Recently, alignment-free methods based on kmer composition have proven their ability to explore the accessory genome. However, they lead to redundant descriptions and results which are hard to interpret.

15

**Methods:** Here, we introduce DBGWAS, an extended kmer-based GWAS method producing interpretable genetic variants associated with phenotypes. Relying on compacted De Bruijn graphs (cDBG), our method gathers cDBG nodes identified by the association model into subgraphs defined from their neighbourhood in the initial cDBG. DBGWAS is fast, alignment-free and only requires a set of contigs and phenotypes. It produces annotated subgraphs representing local polymorphisms as well as mobile genetic elements (MGE) and offers a graphical framework to interpret GWAS results.

16

**Results:** We validated our method using antibiotic resistance phenotypes for three bacterial species. DBGWAS recovered known resistance determinants such as mutations in core genes in *Mycobacterium tuberculosis* and genes acquired by horizontal transfer in *Staphylococcus aureus* and *Pseudomonas aeruginosa* – along with their MGE context. It also enabled us to formulate new hypotheses involving genetic variants not yet described in the antibiotic resistance literature.

17

**Conclusion:** Our novel method proved its efficiency to retrieve any type of phenotype-associated genetic variant without prior knowledge. All experiments were computed in less than two hours and produced a compact set of meaningful subgraphs, thereby outperforming other GWAS approaches and facilitating the interpretation of the results.

18

**Availability:** Open-source tool available at <https://gitlab.com/leoisl/dbgwas>

19

43

## Introduction

44

The aim of Genome-Wide Association Studies (GWAS) is to identify associations between genetic variants and a phenotype observed in a population. They have recently emerged as an important tool in the study of bacteria, given the availability of large panels of bacterial genomes combined with phenotypic data (Farhat et al., 2013; Sheppard et al., 2013; Alam et al., 2014; Chewapreecha et al., 2014; Earle et al., 2016; Lees et al., 2016; Jaillard et al., 2017b).

51

GWAS require encoding the genomic variation as numerical factors. The most common approaches rely on single nucleotide polymorphisms (SNPs), defined by aligning all genomes in the panel against a reference genome (Farhat et al., 2013; Alam et al., 2014; Chewapreecha et al., 2014) and on gene presence/absence, using a pre-defined collection of genes (Earle et al., 2016; Jaillard et al., 2017b). Relying on SNPs or gene presence/absence is reasonable when studying species whose genomic variations can be summarised by a list of pre-defined biological entities. However, a suitable reference is not always available for bacteria, particularly for species with a large accessory genome – the part of the genome which is not present in all strains. Moreover, when focusing on the variation in gene content, one would be unable to cover variants in noncoding regions, including those related to transcriptional and translational regulation (Zhang et al., 2013; Blair et al., 2015).

55

To circumvent these issues and make bacterial genomes amenable to GWAS, recent studies have relied on kmers: all nucleotide substrings of length  $k$  found in the genomes (Sheppard et al., 2013; Earle et al., 2016; Lees et al., 2016). Kmers enable to account for diverse genetic events such as the acquisition of SNPs, (long) insertions/deletions and recombinations. Unlike SNP- or gene-based approaches, kmer-based approaches do not require a reference genome or any assumption on the nature of the causal variants and can even be performed without having to assemble the genome sequences (Le Bras et al., 2016).

60

While kmers can reflect any genomic variation in a panel, they do not themselves represent biological entities. Translating the result of a kmer-based GWAS into meaningful genetic variants typically requires mapping a large and redundant set of short sequences (Sheppard et al., 2013; Earle et al., 2016; Lees et al., 2016; Rahman et al., 2017). Recent studies have suggested reassembling the significantly associated kmers to reduce redundancy and retrieve longer sequences (Lees et al., 2016; Rahman et al., 2017). Nonetheless, kmer representation often loses in interpretability what it gains in flexibility, and the best way to encode the genomic variation in bacterial GWAS is not yet clearly defined (Read and Massey, 2014; Power et al., 2017).

65

70

75

80

85

90

85 Our approach, coined DBGWAS, for *De Bruijn Graph GWAS*, bridges  
 86 the gap between, on the one hand, SNP- and gene-based representations  
 87 lacking the right level of flexibility to cover complete genomic variation, and,  
 88 on the other hand, kmer-based representations which are flexible but not  
 89 readily interpretable. We use De Bruijn graphs (de Bruijn, 1946) (DBGs),  
 90 which are widely used for *de novo* genome assembly (Pevzner et al., 2001;  
 91 Zhang et al., 2011) and variant calling (Iqbal et al., 2012; Le Bras et al.,  
 92 2016). These graphs connect overlapping kmers (here DNA fragments),  
 93 yielding a compact summary of all variations across a set of genomes. Fig-  
 94 ure 1 illustrates the construction of such a graph for a simple example, where  
 95 the only variation among the aligned genomes is a point mutation. DBGs  
 96 also accommodate more complex disparities including rearrangements and  
 97 insertions/deletions (Supplementary Figure S1).




Figure 1: **Compacted DBG construction over a set of sequences differing by a single point mutation.** In this example two sequences  $s_1$  and  $s_2$  of length 12 differ by a single letter. All kmers ( $k = 4$ ) present in these sequences are listed. A) A link is drawn between two kmers when the  $k - 1 = 3$  last nucleotides of the first kmer equal the 3 first nucleotides of the second kmer. B) The bubble pattern represents the SNP C to A; each branch of the bubble represents an allele. C) linear paths of the graph are compacted; the compacted DBG of the example only contains four nodes (unitigs) and represents the same variation as the original DBG, which contained 13 nodes (kmers).

98 DBGWAS relies on the ability of compacted DBGs (cDBGs) to eliminate  
 99 local redundancy, reflect genome variations, and characterise the genomic  
 100 environment of a kmer at the population level. More precisely, we build  
 101 a single cDBG from all the genomes included in the association study (in  
 102 practice, up to thousands). The graph nodes – called unitigs – represent,  
 103 by construction, sequences of variable length and are at the right level of  
 104 resolution for the set of genomes considered, taking into account adaptively

105 the genomic variation. The unitigs are individually tested for association  
106 with the phenotype, while controlling for population structure. The unitigs  
107 found to be phenotype-associated are then localised in the cDBG. Subgraphs  
108 induced by their genomic environment are extracted. They often provide  
109 a direct interpretation in terms of genetic events which results from the  
110 integration of three types of information: 1) the *topology* of the subgraph,  
111 reflecting the nature of the genetic variant, 2) the *metadata* represented by  
112 node size and colour, allowing us to identify which unitigs in the subgraph  
113 are associated to a particular phenotype status, and 3) an optional sequence  
114 *annotation* helping to detect unitig mapping to – or near – a known gene.


115 We benchmarked our novel method using several antibiotic resistance  
116 phenotypes within three bacterial species of various degrees of genome plas-  
117 ticity: *Mycobacterium tuberculosis*, *Staphylococcus aureus* and *Pseudomonas*  
118 *aeruginosa*. The subgraphs built from significant unitigs described SNPs  
119 or insertions/deletions in both core and accessory regions and were consis-  
120 tent with results obtained with a targeted resistome-based GWAS approach.  
121 However, novel genotype-to-phenotype associations were also suggested.

## 122 Results

123 DBGWAS generated a set of ordered subgraphs for every panel of micro-  
124 bial strains and tested antibiotics. It computed the q-values for all the  
125 unitigs and ordered the subgraphs according to the smallest of their unitig  
126 q-value, denoted as  $\min_q$ . The top subgraphs therefore represented the  
127 genomic environment of the unitigs most significantly associated with the  
128 tested phenotype, as discussed in Section *step 3* of the Methods section.

129 The subgraphs we describe below were obtained with DBGWAS using  
130 default parameters plus the annotation option. DBGWAS was only provided  
131 with contigs and their related phenotypes and did not use any prior infor-  
132 mation as to the nature or location of potential causal variants. Each run  
133 on the three tested species only took between 16 min and 90 min on a single  
134 core and required less than 12Gb of memory (Supplementary Table S1).

135 A synthetic description of the subgraphs discussed in the results is pro-  
136 vided in Table 1, while a description of the top subgraphs obtained for all  
137 tested antibiotics, is provided in Supplementary Tables S3 to S5. The sub-  
138 graphs themselves are available at [http://leoisl.gitlab.io/DBGWAS\\_](http://leoisl.gitlab.io/DBGWAS_support/experiments)  
139 *support/experiments*.



**Figure 2: Different types of genetic events identified by DBGWAS.** Each subgraph represents a distinct genetic event. Panel A shows the subgraph with lowest  $\min_q$  extracted for *P. aeruginosa* levofloxacin resistance. It was composed of 27 unitigs, 5 of which were significantly associated with resistance. Susceptible unitigs are shown in blue, while resistant unitigs in red. All unitigs of this subgraph mapped to the *gyrA* gene. Panels B, C, D, E correspond to the top subgraphs obtained for other panels/phenotypes. The larger the node, the higher the allele frequency. Grey nodes were present in  $> 99\%$  or  $< 1\%$  of the strains and were not tested. Bright blue (resp. bright red) nodes were present almost exclusively in susceptible (resp. resistant) strains. Pale blue (resp. pale red) nodes were present with a larger frequency in susceptible (resp. resistant) strains. Circled black nodes mapped to annotated genes.

140 **Coloured bubbles highlight local polymorphism in**  
141 **core genes, accessory genes and noncoding regions**

142 For *P. aeruginosa* levofloxacin resistance, the subgraph obtained with the  
143 lowest  $\min_q$  highlighted a polymorphic region in a core gene (Figure 2A).  
144 Indeed, it showed a linear structure containing a complex bubble, with a  
145 fork separating susceptible (blue) and resistant (red) strains. The anno-  
146 tation revealed that all unitigs in this subgraph mapped to the quinolone  
147 resistance-determining region (QRDR) of the *gyrA* gene. *gyrA* codes for a  
148 subunit of the DNA gyrase targeted by quinolone antibiotics such as lev-  
149 ofloxacin and its alteration is therefore a prevalent and efficient mechanism of  
150 resistance (Hooper and Jacoby, 2015; Lowy, 2003). In all our experiments  
151 related to quinolone resistance, DBGWAS identified QRDR mutations in  
152 either *gyrA* or *parC*, which codes for another well-known quinolone target:  
153 *P. aeruginosa* levofloxacin (first subgraph, *gyrA*:  $\min_q = 7.21 \times 10^{-29}$  and  
154 second, *parC*:  $5.68 \times 10^{-06}$ ), *S. aureus* ciprofloxacin (first, *parC*:  $\min_q =$   
155  $8.67 \times 10^{-104}$  and second, *gyrA*:  $2.21 \times 10^{-76}$ ), and ofloxacin resistance in  
156 *M. tuberculosis*, whose genome does not contain the *parC* gene (Piton et al.,  
157 2010) (first, *gyrA*:  $\min_q = 9.66 \times 10^{-144}$ ).

158 For *P. aeruginosa* amikacin resistance, the top subgraph ( $\min_q = 5.86 \times$   
159  $10^{-9}$ ) highlighted a SNP in an accessory gene (Figure 2B). As in Figure 2A,  
160 it contained a fork separating a blue and a red node. However, other remain-  
161 ing nodes were not grey: they represented an accessory sequence because  
162 they were not present in all the strains. Most of these nodes were pale-red,  
163 showing that the accessory sequence was more frequent in resistant sam-  
164 ples. The annotation revealed that this subgraph corresponded to *aac(6')*,  
165 a gene coding for an aminoglycoside 6-acetyltransferase, an enzyme capable  
166 of inactivating aminoglycosides, such as amikacin, by acetylation (Lambert,  
167 2002). Most unitigs in this gene had a low association with resistance, ex-  
168 cept for the ones describing this particular SNP. This mutation, L83S, lying  
169 in the enzyme binding site, was previously shown to be responsible for sub-  
170 strate specificity alteration in a strain of *Pseudomonas fluorescens* (Lambert  
171 et al., 1994). It appeared thus to increase the amikacin acetylation ability of  
172 *aac(6')*, making its association to amikacin resistance more significant than  
173 the gene presence itself.

174 Finally, for *M. tuberculosis* ethionamide resistance, the top subgraph  
175 ( $\min_q = 7.86 \times 10^{-11}$ , Figure 2C) represented a polymorphic region in a  
176 core gene promoter. The subgraph was mostly grey and linear with a lo-  
177 calised blue and red fork. The most reliable annotation for this subgraph was  
178 *fabG1* (also known as *mabA*), a core gene previously shown to be involved in  
179 ethionamide and isoniazid resistance (Lee et al., 2000; Farhat et al., 2016).  
180 None of the significantly associated unitigs mapped to the *fabG1* gene, but  
181 their close neighbours did (highlighted in Figure 2C by black circles), sug-

182 gesting that the detected variant was located in the promoter region of the  
183 gene. This was confirmed by mapping the significant unitig sequences using  
184 the Tuberculosis Mutation database of the *mubii* resource (Flandrois et al.,  
185 2014).

186 Long single-coloured paths denote mobile genetic  
187 element insertions

For *S. aureus* resistance to methicillin, the top subgraph ( $\min_q = 7.68 \times 10^{-188}$ ), shown in Figure 2D, revealed a gene cassette insertion. It contained a long path of red nodes, and a branching region including another red node path. The first path mapped to the *mecA* gene, extensively described in this context and known to be carried by the Staphylococcal Cassette Chromosome *mec* (SCC*mec*) (Lowy, 2003; IWG-SCC consortium, 2009; Gordon et al., 2014). The other part of the subgraph represented a >5,000 bp fragment of the cassette. It was less linear because it summarised several types of the cassette differing by their structure and gene content (IWG-SCC consortium, 2009). The next subgraphs represented other regions of the same cassette. Interestingly, considering a greater number of unitigs to build the subgraphs would lead to merging these individual subgraphs, representing related genomic regions, into a single subgraph. This can be done by increasing the Significant Features Filter (*SFF*) parameter value which defines the unitigs used to build the subgraphs. By default, the unitigs corresponding to the 100 lowest q-values are retained (*SFF* = 100). Increasing the *SFF* value to 150 (150th q-value =  $1.60 \times 10^{-27}$ ) allowed us to reconstruct the entire SCC*mec* cassette, as shown in Supplementary Figure S3.

For *S. aureus* erythromycin resistance, a unique subgraph was generated ( $\min_q = 2.69 \times 10^{-100}$ ). As shown in Figure 2E, the subgraph described the circular structure of a 2,500 bp-long plasmid known to carry the causal *ermC* gene (Westh et al., 1995; Gordon et al., 2014) together with a replication and maintenance protein in strong linkage disequilibrium with *ermC*.

For *P. aeruginosa* amikacin resistance, the third subgraph ( $\min_q = 2.21 \times 10^{-6}$ ) represented a 10,000 bp plasmid acquisition. Using the NCBI nucleotide database (Benson et al., 2012), most of the unitigs in this subgraph mapped to the predicted prophage regions of an integrative and conjugative plasmid, whose structure was recently described as the pHS87b plasmid in the amikacin resistant *P. aeruginosa* HS87 strain (Bi et al., 2016). Supplementary Figures S4 and S5 provide more examples of MGEs recovered by DBGWAS, and Section *step 3* of the Methods discusses *SFF* default value and tuning.

**Table 1: Resistance determinants identified by DBGWAS for *S. aureus* (SA), *M. tuberculosis* (TB) and *P. aeruginosa* (PA) panels.** For each antibiotic, subgraphs were reported with their rank, number of significant unitigs over all unitigs in the subgraph (Sign. unit.), q-value of the unitig with the lowest q-value ( $\min_q$ ), the corresponding estimated effect ( $\beta$  coefficient of the linear mixed model) and annotation of the subgraph. The type of event represented by the subgraph was colour-coded as: yellow for MGE, light blue for local polymorphism in gene (LPG), and dark blue for local polymorphism in noncoding region (LPN). Known positives were indicated in dark green (Pos), regions in LD with a positive in light green (LD), determinants caused by cross-resistance in orange (CR) and unknown determinants in grey (Ukn).

Panel	Phenotype	Rank	Sign. unit.	$\min_q$	Est. effect	Annotation	Type	Pos.
SA	Methicillin	1	71/565	7.68E-188	9.49E-01	<i>mecA</i> + 7000 bp of SC <i>Cmec</i>	MGE	Pos
		2	99/735	3.39E-72	8.65E-01	6000 bp of SCC <sub>mec</sub>	MGE	LD
		3	11/190	2.14E-61	8.13E-01	2000 bp of SCC <sub>mec</sub>	MGE	LD
		4	13/117	2.29E-37	9.57E-01	1500 bp of SCC <sub>mec</sub>	MGE	LD
	Ciprofloxacin	1	7/57	8.67E-104	-8.93E-01	<i>parC</i> QRDR	LPG	Pos
		2	7/31	2.21E-76	9.55E-01	<i>gyrA</i> QRDR	LPG	Pos
	Erythromycin	1	110/510	2.69E-100	8.23E-01	<i>ermC</i> + circular plasmid	MGE	Pos
	Fusidic acid	1	7/50	2.75E-136	-9.10E-01	<i>fusA</i>	LPG	Pos
		2	214/882	7.94E-49	9.24E-01	<i>fusC</i> + SCC <sub>fusC</sub> cassette	MGE	Pos
		3	22/260	5.35E-43	9.24E-01	1,500 bp of SCC <sub>fusC</sub>	MGE	LD
TB		3	1/72	5.35E-43	9.24E-01	200 bp of SCC <sub>fusC</sub>	MGE	LD
		5	5/64	2.02E-22	-8.88E-01	<i>parN</i>	LPG	Ukn
	Trimethoprim	1	7/54	8.38E-24	9.69E-01	<i>folA</i>	LPG	Pos
		3	11/70	9.30E-18	-9.66E-01	<i>btw.</i> hyp. prot. & VOC prot.	LPN	Ukn
		4	2/30	6.82E-10	-6.32E-01	<i>ybaK</i>	LPG	Ukn
		4	173/1193	1.30E-205	8.73E-01	<i>aac(6')</i> gene within a plasmid	MGE	Pos
	Gentamicin	2	127/367	9.02E-75	7.51E-01	seq. of plasmid carrying <i>aac(6')</i>	MGE	LD
		3	2/23	9.01E-53	6.34E-01	seq. of plasmid carrying <i>aac(6')</i>	MGE	LD
		4	1/29	1.04E-40	5.79E-01	seq. of plasmid carrying <i>aac(6')</i>	MGE	LD
	Q	5	2/56	1.49E-33	-8.31E-01	<i>odhB</i>	LPG	Ukn
PA	Rifampicin	1	36/115	4.84E-70	-5.77E-01	<i>rpoB</i> RRDR	LPG	Pos
		2	6/37	4.35E-20	-3.55E-01	<i>katG</i>	LPG	CR
		3	5/41	4.02E-08	-2.24E-01	<i>embB</i> M306V	LPG	Pos
		4	5/30	3.70E-31	5.44E-01	<i>rpsL</i> (30S ribos. protein S12)	LPG	Pos
	Streptomycin	2	6/37	1.06E-28	-4.28E-01	<i>katG</i>	LPG	CR
		3	25/113	2.87E-16	-3.39E-01	<i>rpoB</i> RRDR	LPG	CR
		4	6/45	1.40E-09	-2.71E-01	<i>embB</i> M306V	LPG	CR
		5	8/31	2.86E-09	-5.35E-01	<i>rps</i> , 16S rRNA C517T	LPG	Pos
		6	13/69	9.18E-05	-2.16E-01	<i>gyrA</i> QRDR	LPG	CR
		7	2/20	9.43E-04	7.46E-01	<i>espGI</i>	LPG	Ukn
PA	Ofloxacin	1	31/85	9.66E-144	-8.88E-01	<i>gyrA</i> QRDR	LPG	Pos
		2	9/68	1.59E-04	5.07E-01	<i>ubiA</i> (Rv3806c)	LPG	CR
		3	3/32	3.86E-02	-7.46E-01	Rv3909	LPG	Ukn
	Ethionamide	1	9/39	7.86E-11	-4.62E-01	<i>fabG1</i> promoter	LPN	Pos
		2	15/47	5.16E-10	-4.06E-01	<i>gyrA</i> QRDR	LPG	CR
		3	4/26	5.55E-04	3.19E-01	<i>rps</i> , 16S rRNA A1401G	LPG	CR
		3	3/24	9.58E-36	8.83E-01	<i>rpoB</i> 11187T (out. RRDR)	LPG	Ukn
		1	6/68	3.66E-39	9.05E-01	Rv2000	LPG	Ukn
		1	3/27	3.66E-39	9.05E-01	<i>espA</i> promoter	LPN	Ukn
		1	4/83	5.86E-09	6.21E-01	SNP in <i>aac(6')</i>	LPG	Pos
PA	Amikacin	1	4/83	5.86E-09	6.21E-01	DEAD/DEAH box helicase	LPG	Pos
		2	3/82	1.37E-06	6.62E-01	plasmid mapping on pHS87b	MGE	LD
		3	38/315	2.21E-06	5.23E-01			
PA	Levofloxacin	1	5/27	7.21E-29	-8.84E-01	<i>gyrA</i> QRDR	LPG	Pos
		2	5/29	5.68E-06	-7.37E-01	<i>parC</i> QRDR	LPG	Pos
		3	5/38	1.87E-02	6.88E-01	Histidine kinase/response regulator (HK/RR)	LPG	Ukn

Comparison of DBGWAS to reference- and kmer-based methods: DBGWAS reports expected variants without prior knowledge, with the highest computational efficiency.

DBGWAS relies on bugwas (Earle et al., 2016) – a state-of-the-art association model for bacterial GWAS – to test for significant associations between unitigs and phenotypes. The performance of detecting true associations using unitigs was previously assessed using simulated data (Jaillard et al., 2017a). In this preliminary study, we showed that the linear mixed model implemented by bugwas presented the best power to detect genuine associations under different population structure hypotheses, among several association models.

Here, we evaluated DBGWAS using real data. Although resistance determinants are not perfectly and exhaustively known in any species, some resistance mechanisms are well described enough to allow evaluation on real data. This is the case of target alteration in fluoroquinolone resistance or, in *M. tuberculosis* resistance, to antibiotics of the aminoglycoside family. We thus compared resistance determinants obtained by DBGWAS for *M. tuberculosis* (aminoglycoside) streptomycin resistance and *P. aeruginosa* (fluoroquinolone) levofloxacin resistance, to determinants obtained by a resistome-based GWAS (RWAS) strategy (Davis et al., 2016; Jaillard et al., 2017b), as described in the Methods section, and by two other recent kmer-based methods: SEER (Lees et al., 2016) and HAWK (Rahman et al., 2017). For *P. aeruginosa* levofloxacin resistance (Figure 3A), DBGWAS and SEER found both known causal determinants reported by the RWAS strategy, *gyrA* and *parC*, while HAWK only reported *gyrA*. SEER reported 403 kmers, all linked to *gyrA* and *parC* contrary to others methods that all reported less than 10 features, among which new hypotheses. For *M. tuberculosis* streptomycin resistance (Figure 3B), the four methods reported both known causal determinants *rpsL* and *rrs*, however not always in the same order. Indeed, while the RWAS and DBGWAS methods found the causal *rpsL* determinant as the first position, SEER and HAWK reported first the *katG* determinant. All the methods identified several markers described for other antibiotics. This observed cross-resistance to antibiotics is a well described phenomenon in *M. tuberculosis* species (Traore et al., 2000; Palomino and Martin, 2014). Compared to SEER and HAWK, DBGWAS produced a smaller number of features (24 *versus* several thousands), in a shorter time (1h 18m *versus* >9h), without loss of sensitivity regarding the detection of resistance markers. Additional results for all the antibiotics can be found in Supplementary Tables S6 and S7 for RWAS, and in Supplementary Tables S3 and S5 for DBGWAS.

In addition to resistance markers, the three kmer-based approaches reported several unknown determinants, not described in the context of resistance.

A. PA Levofloxacin				
Legend	RWAS	DBGWAS	SEER	HAWK
Time (mem)		34m (3.2)	2h47m (14.5)	1h (4.3)
Nb reported	2 variants	5 subgraphs	403 kmers *	9 reassembled kmers
Known positive	<u><i>gyrA</i></u> (2.11E-22) <i>parC</i> (1.83E-05)	<u><i>gyrA</i></u> (7.21E-29) <i>parC</i> (5.68E-06)	<u><i>gyrA</i></u> (2.00E-17) <i>parC</i> (5.73E-10)	<u><i>gyrA</i></u> (2.82E-14)
Unknown		HK/RR (1.87E-02) transposase <i>topA</i>		<i>pnp</i> (1.01E-13) <i>hsIV</i> unchar. prot. <i>y4hP</i> unchar. prot. <i>y4rG</i> endonuclease 4 transposase <i>macB</i>

B. TB Streptomycin				
Legend	RWAS	DBGWAS	SEER	HAWK
Time (mem)		1h18m (4.3)	10h10m (102.4)	9h18m (12.3)
Nb reported	28 variants	24 subgraphs	51,219 kmers *	2,049 reassembled kmers
Known positive	<u><i>rpsL</i></u> (1.96E-33) <i>rrs</i> (5.40E-08)	<u><i>rpsL</i></u> (3.70E-31) <i>rrs</i> (2.86E-09)	<u><i>rpsL</i></u> (1.26E-54) <i>rrs</i> (2.55E-16)	<u><i>rpsL</i></u> (5.72E-47) <i>rrs</i> (3.45E-20)
Determinant described for other antibiotics	<i>katG</i> (2.61E-30) <i>rpoB</i> <i>gidB</i> <i>gyrA</i> <i>embB</i> <i>fabG1</i> promoter <i>pncA</i> <i>rpoC</i> <i>inhA</i>	<i>katG</i> (1.06E-28) <i>rpoB</i> <i>embB</i> <i>gyrA</i> <i>gidB</i> <i>fabG1</i> promoter <i>rpoC</i> <i>ubiA</i>	<i>katG</i> (2.12E-71) <i>rpoB</i> (1.57E-69) <i>embB</i> <i>gyrA</i> <i>ethA</i> <i>fabG1</i> promoter	<i>katG</i> (1.44E-57) <i>embB</i> <i>kasA</i> <i>embC</i> <i>gyrA</i> <i>iniA</i> <i>embA</i> <i>embR</i> <i>gidB</i> <i>tsnR</i> <i>rpoB</i> <i>pncA</i> <i>ethA</i>
Unknown (top list)		<i>rpsN</i> (1.20E-03) <i>espG1</i> <i>mmpS1</i> <i>rnj</i> Rv2672 <i>espA</i> promoter Rv2456c promoter <i>whiB6</i> ....	<i>pyrB</i> (1.13E-19) <i>aspS</i> Alkanesulfonate monooxygenase <i>folD</i> <i>mmpS1</i> <i>dsbE</i> <i>cysNC</i> <i>pncB1/2</i> ....	<i>recF</i> (2.93E-57) Rv1199c Rv1313c <i>leuS</i> PPE47/PPE48 <i>espA</i> promoter <i>aspS</i> <i>mmpS1</i> ....

\* In SEER output, 225 kmers were annotated *gyrA* and 178 *parC*

B. TB Streptomycin				
Legend	RWAS	DBGWAS	SEER	HAWK
Time (mem)		1h18m (4.3)	10h10m (102.4)	9h18m (12.3)
Nb reported	28 variants	24 subgraphs	51,219 kmers *	2,049 reassembled kmers
Known positive	<u><i>rpsL</i></u> (1.96E-33) <i>rrs</i> (5.40E-08)	<u><i>rpsL</i></u> (3.70E-31) <i>rrs</i> (2.86E-09)	<u><i>rpsL</i></u> (1.26E-54) <i>rrs</i> (2.55E-16)	<u><i>rpsL</i></u> (5.72E-47) <i>rrs</i> (3.45E-20)
Determinant described for other antibiotics	<i>katG</i> (2.61E-30) <i>rpoB</i> <i>gidB</i> <i>gyrA</i> <i>embB</i> <i>fabG1</i> promoter <i>pncA</i> <i>rpoC</i> <i>inhA</i>	<i>katG</i> (1.06E-28) <i>rpoB</i> <i>embB</i> <i>gyrA</i> <i>gidB</i> <i>fabG1</i> promoter <i>rpoC</i> <i>ubiA</i>	<i>katG</i> (2.12E-71) <i>rpoB</i> (1.57E-69) <i>embB</i> <i>gyrA</i> <i>ethA</i> <i>fabG1</i> promoter	<i>katG</i> (1.44E-57) <i>embB</i> <i>kasA</i> <i>embC</i> <i>gyrA</i> <i>iniA</i> <i>embA</i> <i>embR</i> <i>gidB</i> <i>tsnR</i> <i>rpoB</i> <i>pncA</i> <i>ethA</i>
Unknown (top list)		<i>rpsN</i> (1.20E-03) <i>espG1</i> <i>mmpS1</i> <i>rnj</i> Rv2672 <i>espA</i> promoter Rv2456c promoter <i>whiB6</i> ....	<i>pyrB</i> (1.13E-19) <i>aspS</i> Alkanesulfonate monooxygenase <i>folD</i> <i>mmpS1</i> <i>dsbE</i> <i>cysNC</i> <i>pncB1/2</i> ....	<i>recF</i> (2.93E-57) Rv1199c Rv1313c <i>leuS</i> PPE47/PPE48 <i>espA</i> promoter <i>aspS</i> <i>mmpS1</i> ....

\* In SEER output, 200 kmers were annotated *rpsL*, 51 *rrs* 207 *katG*, and 169 *rpoB*.

**Figure 3: Resistance determinants found by the 4 methods, for *M. tuberculosis* streptomycin and *P. aeruginosa* levofloxacin resistances.** In this figure, we report deduplicated annotations of features identified as significant with the default parameters (p-value for SEER and HAWK or q-value for RWAS and DBGWAS). The total number of reported features is given in the header. For kmer-based methods, annotations were retrieved by mapping unitig/kmer sequences on the resistance and Uniprot databases. Green cells correspond to resistance determinants already described in the literature, orange cells to resistance determinants described for association with other antibiotics (annotations not found by RWAS are written in bold), and grey cells to unknown determinants. Within each category, annotations are ordered by increasing minimum p/q-values, corresponding to the lowest p/q-value found for each annotation before deduplication (p/q-values are reported only for the most significant annotations). For each method, the annotation with the lowest p/q-values is underlined. The execution time and memory load (in Gigabytes) are shown in the header (see also Supplementary Table S2).

262 tance. Within them, in the context of streptomycin resistance, the *mmpS1*  
263 annotation was reported by the three methods, but not by the RWAS  
264 approach, as this gene was not included in the targeted approach prior.  
265 More generally, any reference-based approaches such as SNP- or gene-based  
266 GWAS or RWAS are limited in the context of new marker discovery, espe-  
267 cially for species with a large accessory genome, since any causal variant  
268 absent from the chosen reference would remain non-tested. Besides be-  
269 ing time-consuming, preparing such a list of genetic variants can even be  
270 problematic for bacterial species without extensive annotation nor reference  
271 availability.

272 Agnostic approaches avoid the difficulty of designing an exhaustive vari-  
273 ant database for the GWAS. However, HAWK and SEER reported several  
274 thousands kmers for *M. tuberculosis* streptomycin resistance, while DBG-  
275 WAS reported only 24 annotated subgraphs without missing expected de-  
276 terminants (Figure 3A). Indeed, when several phenotype-associated unitigs  
277 were found within a particular region of the genome, DBGWAS gathered  
278 them into a single subgraph enriched with metadata and annotation (Sup-  
279 plementary Section 6), providing a valuable interpretation framework. As  
280 an example, the top subgraph for rifampicin resistance ( $\min_q = 4.84 \times 10^{-70}$ )  
281 contained 36 significant unitigs, either blue or red. Instead of a single point  
282 mutation, this subgraph represented a polymorphic region known as the  
283 rifampicin resistance-determining region (RRDR) of the *rpoB* gene. The  
284 unitig with the lowest q-value covered several mutant positions, defining a  
285 haplotype strongly associated with rifampicin resistance. Where DBGWAS  
286 reported in this case only one subgraph, SEER, for instance, reported 470  
287 kmers with the *rpoB* annotation.

288 Finally, DBGWAS took less than 2 hours in all our experiments, while  
289 SEER took more than one week in some experiments, and HAWK usually  
290 ran in less than one day but failed on the most complex dataset composed of  
291 genomes of different species. Moreover, SEER required much more memory  
292 (up to 100Gb) than DBGWAS and HAWK (Supplementary Table S2).

## 293 **DBGWAS suggests novel hypotheses**

294 As DBGWAS screens the genomic variations without prior knowledge, it  
295 documented associations never previously described in resistance literature.

296 In our *P. aeruginosa* panel, the second subgraph obtained for amikacin  
297 resistance ( $\min_q = 1.37 \times 10^{-6}$ ) gathered unitigs mapping to the 3' region  
298 of a DEAD/DEAH box helicase known to be involved in stress tolerance in  
299 *P. aeruginosa* (Illakkiam et al., 2014). The unitig with the lowest q-value  
300 was present in 13 of 47 resistant strains and in only 1 of 233 susceptible  
301 strains and represented a C-C haplotype summarising two mutated posi-  
302 tions: 2097 and 2103. In *P. aeruginosa* levofloxacin resistance, the third

303 subgraph ( $\min_q = 1.87 \times 10^{-2}$ ) represented a L650M amino-acid change in  
304 a hybrid sensor histidine kinase/response regulator. Such two-components  
305 regulatory systems play important roles in the adaptation of organisms to  
306 their environment, for instance in the regulation of biofilm formation in *P.*  
307 *aeruginosa* (Ali-Ahmad et al., 2017), and as such may play a role in antibiotic  
308 resistance.

309 In *S. aureus*, polymorphisms within genes not known to be related to  
310 resistance were identified for several antibiotics: *purN* ( $\min_q = 2.02 \times 10^{-22}$ )  
311 for fusidic acid, *odhB* ( $\min_q = 1.49 \times 10^{-33}$ ) for gentamicin, *ybaK* and *mqa1*  
312 ( $\min_q = 9.30 \times 10^{-18}$ , resp.  $6.82 \times 10^{-10}$ ) for trimethoprim. None of these  
313 genes have been associated with antibiotic resistance before, to the best of  
314 our knowledge.

315 In *M. tuberculosis*, polymorphisms in two genes encoding proteins involved in *cell wall and cell processes*, *espG1* and *espA*, were found associated  
316 with streptomycin (seventh subgraph,  $\min_q = 9.43 \times 10^{-4}$ ) and XDR phenotype  
317 (third subgraph,  $\min_q = 9.58 \times 10^{-36}$ ) respectively. Again, these genes  
318 have never been reported in association with antibiotic resistance before.  
319

320 Although experimental validation would be required to tell whether these  
321 hypotheses are false positive (e.g., in linkage with causal variants) or actual  
322 resistance mechanisms not yet documented, DBGWAS is a valuable tool  
323 for novel candidate screening. Moreover it provides a first level of variant  
324 description (SNPs in gene or promoter, MGE, etc.) which can directly drive  
325 the biological validation.

## 326 Discussion

327 In this article we introduce an efficient method for bacterial GWAS. Our  
328 method is agnostic: it screens all genomic variations and is able to identify  
329 potential new causal variants as different as SNPs or (MGE) inser-  
330 tions/deletions. It performs as well as the current SNP- and gene-based  
331 gold standard approaches for retrieving known determinants, while these  
332 standard approaches require strong prior assumptions often limiting the  
333 variant search space and requiring fastidious preprocessing.

334 Our original method, exploiting the genetic environment of the signifi-  
335 cant kmers, through their neighbourhood in the cDBG, provides a valuable  
336 interpretation framework. Because it uses only contig sequences as input, it  
337 allows GWAS on bacterial species for which the genomes are still poorly an-  
338 notated or lack a suitable reference genome. Our method, DBGWAS, makes  
339 bacterial GWAS possible in less than two hours using a desktop computer,  
340 outperforming state-of-the-art kmer-based approaches.

341 Underlying our method, graph-based genome sequence representations  
342 such as DBGs, extend the notion of the reference genome to cases where a  
343 single sequence stops being an appropriate approximation (Marschall et al.,

344 2016; Paten et al., 2017). As demonstrated in this paper, they pave the  
345 way to GWAS on highly plastic bacterial genomes and would also be useful  
346 for microbiomes (Baaijens et al., 2017) or human tumours (Rahman et al.,  
347 2017).

348 DBGWAS could be extended to different statistical tasks by adapting its  
349 underlying association model, to allow for continuous phenotypes or iden-  
350 tifying epistatic effects, for instance. The interpretability of the extracted  
351 subgraphs could also be improved by training a machine learning model  
352 to predict which types of event they represent. This automated labelling  
353 could guide users in their interpretation and allow them to search for specific  
354 events, such as SNPs in core genes or rearrangements. Knowing the type  
355 of event that a subgraph represents could also be of use for constructing  
356 a method controlling false discovery rate at the genetic event level (SNPs,  
357 MGE insertion) instead of at the unitig level.

358 A variety of current studies describes computerised models for defining  
359 a genomic antibiogram and hopes are high that such technologies will re-  
360 place the classical methods. Extensive studies have been performed for a  
361 multitude of organisms and the more clonal the bacterial species, the more  
362 direct homology searches for resistance genes become reliable (Dunne Jr  
363 et al., 2017). Several studies have already demonstrated that genomic an-  
364 tibiograms are at least as good as classic phenotypic ones (Gordon et al.,  
365 2014). Contrary to our approach, these studies require extensive resistance  
366 marker databases. DBGWAS will surely contribute to the extension of such  
367 databases or to the development of agnostic genomic antibiograms.

368 In conclusion, we demonstrate for three medically important bacterial  
369 species that resistance markers can be detected rapidly with relative ease,  
370 using simple computer equipment. New links between genomic variations  
371 and phenotypes can be inferred, providing our method with a clear advan-  
372 tage in comparison to existing procedures. Using our graphical interface will  
373 provide future users in all domains of microbiology with an enhanced insight  
374 into genotype to phenotype correlation, also beyond antibiotic resistance.  
375 This will include complex traits such as biofilm formation, epidemicity and  
376 virulence.

## 377 Methods

### 378 Encoding genomic variation with compacted DBGs

379 DBGs are directed graphs that efficiently represent all the information con-  
380 tained in a set of sequences. Nodes represent all the unique kmers (genome  
381 sequence substrings of length  $k$ ) extracted from the input sequences. Edges  
382 represent  $(k - 1)$ -exact-overlaps between kmers: an edge connects a node  
383  $n_1$  to a node  $n_2$  if and only if the  $(k - 1)$ -length-suffix of  $n_1$  equals the

384  $(k - 1)$ -length-prefix of  $n_2$  (Figure 1A).

385 These graphs can be compacted into cDBGs by merging linear paths (sequences of nodes not linked to more than two other nodes) into a single node  
 386 referred to as a *unitig* (Butler et al., 2008; Zerbino and Birney, 2008; Chikhi  
 387 et al., 2016) (Figure 1C). Compaction yields a graph with locally optimal  
 388 resolution: regions of the genome which are conserved across individuals  
 389 are represented by long unitigs, while regions which are highly variable are  
 390 fractioned into shorter unitigs (Supplementary Figure S1).

391 We perform GWAS on strains encoded by their unitig (rather than kmer)  
 392 content, and use the cDBG neighbourhood of significantly associated unitigs  
 393 as a proxy for their genomic environment. Figure 4 summarises the main  
 394 steps of the process. The code implementing this process is available at  
 395 <https://gitlab.com/leoisl/dbgwas/> under the GNU Afferro General  
 396 Public License.




Figure 4: **DBGWAS pipeline.** DBGWAS takes as input draft assemblies and phenotype data for a panel of bacterial strains. Variant matrix  $X$  is built in step 1 using cDBG nodes. Variants are tested in step 2 using a linear mixed model. Significant variants are post-processed in step 3 to provide an interactive interface assisting with their interpretation.

398

## Representing strains by their unitig content (step 1)

399

**cDBG construction.** We build a single DBG from all genomes given as input using the GATB C++ library (Drezen et al., 2014). We start from contigs rather than reads to be robust to sequencing errors. Consequently, we do not need to filter out low abundance kmers, allowing for the exploration of any variation present in the set of input genomes.

400

We use a  $k = 31$  length for our kmers, as it produced the best performance to retrieve known markers in a pilot experiment (Supplementary Figure S8). The ideal choice of  $k$ , however, depends on many factors, including the assembly quality, complexity of the input genomes, or presence of repeats. Sensibility analysis to the choice of  $k$  is extensively presented in Supplementary Section 5. We then compact the DBG using a graph traversal algorithm, which identifies all linear paths in the DBG – each forming a unitig in the cDBG. During this step, we also associate each kmer index to its corresponding unitig index in the cDBG.

401

**Unitig presence across genomes.** Each genome is represented by a vector of presence/absence of each unitig in the cDBG. To do so, we query the unitig associated to each kmer in a given genome. This procedure is efficient because it relies on constant time operations. Firstly, we use GATB’s Minimal Perfect Hash Function (MPHF) (Limasset et al., 2017) to retrieve the index of a given kmer, and then we use the association between kmer and unitig indexes to know which unitigs the given genome contains. Since these two operations take constant time, producing this vector representation for a genome takes linear time on the size of the genome. It is important to note that the GATB’s MPHF can be successfully applied here because we always use the same list of kmers, *i.e.*, after building the DBG, the set of kmers is fixed and not updated, and because we always query kmers that are guaranteed to be in the DBG (since we do not filter out any kmer).

402

The unitig description on all the input genomes is stored into a matrix  $U$ :

$$U_{i,j} = \begin{cases} 1, & \text{if the } j\text{-th unitig is present in the } i\text{-th input genome;} \\ 0, & \text{otherwise.} \end{cases}$$

403

We then transform the matrix  $U$  into  $Z$ , giving minor allele description (Earle et al., 2016).  $Z$  is identical to  $U$  except for columns with a mean larger than 0.5, which are complemented:  $Z_j = 1 - U_j$  for these columns.

404

We then restrict  $Z$  to its set of unique columns. If several unitigs have the same minor allele presence pattern, then they will be represented by a single column. Keeping duplicates would lead to performing the same statistical test several times. Finally, we filter out columns whose average is below 0.01. We denote the de-duplicated, filtered matrix of patterns by  $X$ .

435 **Testing unitigs for association with the phenotype**  
436 **(step 2)**

437 Human GWAS literature extensively discusses how testing procedures can  
438 result in spurious associations if the effect of the population structure is  
439 not taken into account (Balding, 2006; Zhou and Stephens, 2014; Widmer  
440 et al., 2014). Population structures can be strong in bacteria because of their  
441 clonality (Falush and Bowden, 2006; Earle et al., 2016; Lees et al., 2016). A  
442 preliminary performance analysis comparing several models for population  
443 structure on both simulated and real data (Jaillard et al., 2017a) showed  
444 that correcting for population structure using LMMs is often preferable to  
445 using a fixed effect correction or not correcting at all.

446 We thus rely on the bugwas method (Earle et al., 2016), which uses the  
447 linear mixed model (LMM) implemented in the GEMMA library (Zhou and  
448 Stephens, 2012) to test for association with phenotypes while correcting for  
449 the population structure. This method also offers the possibility to test for  
450 lineage effects, by calculating p-values for association between the columns of  
451 the matrix representing the population structure, and the phenotype (Earle  
452 et al., 2016).

453 Formally, the LMM represents the distribution of the binarized pheno-  
454 type  $Y_i$ , given the  $j$ -th minor allele pattern  $X_{ij}$  and the population structure  
455 represented by a set of factors  $W \in \mathbb{R}^{n \leq p}$ , by:

$$Y_i = X_{ij}\beta + W_i^T\alpha + \varepsilon_{ij}, \quad j = 1, \dots, p \quad (1)$$

456  $\beta$  is the fixed effect of the tested candidate on the phenotype,  $\alpha$  is the random  
457 effect of the population structure, and  $\varepsilon_{ij} \stackrel{\text{iid}}{\sim} \mathcal{N}(0, \sigma^2)$  are the residuals with  
458 variance  $\sigma^2 > 0$ .  $W$  is estimated from the  $Z$  matrix which includes duplicate  
459 columns representing both core and accessory genome.

460 We test  $H_0 : \beta = 0$  versus  $H_1 : \beta \neq 0$  in equation 1 for each unitig using  
461 a likelihood ratio procedure producing p-values and maximum likelihood  
462 estimates  $\hat{\beta}$ . Finally, we compute the q-values, which are the Benjamini-  
463 Hochberg transformed p-values controlling for false discovery rate (FDR) in  
464 the situation of multiple testing (Benjamini and Hochberg, 1995).

465 **Interpretation of significant unitigs (step 3)**

466 The LMM can be used to identify deduplicated minor allele presence pat-  
467 terns significantly associated with the phenotype at a chosen level. Because  
468 of the deduplication procedure used to build the matrix  $X$ , each of these  
469 patterns can correspond to several unitigs. We now show how the cDBG  
470 can be used in the interpretation step.

471 **Significance threshold.** We select the most significantly associated  
472 patterns by defining a Significant Features Filter (*SFF*). In our experi-

473       ments, we choose not to apply a fixed FDR threshold – even though DBG-  
474       WAS offers this option, by using a *SFF* value between 0 and 1. Different  
475       datasets lead to different q-values, even by several orders of magnitude, and  
476       a single FDR threshold would lead to selecting a large number of unitigs  
477       generating  $> 1000$  subgraphs on some of them (e.g. *S. aureus* ciprofloxacin)  
478       as shown in Supplementary Table S8. Instead, we use  $SFF = 100$ , *i.e.*,  
479       retaining the 100 patterns with lowest q-values. However arbitrary, this  
480       choice is tractable for all datasets and provides satisfactory results in our  
481       experiments. It does not guarantee control of the FDR: only the q-value  
482       provides an estimation of the proportion of false discoveries incurred when  
483       considering patterns below this value. Checking the q-values of the selected  
484       unitigs is therefore essential to assess its significance.

485       **Graph neighbourhoods.** We define the neighbourhood of each sig-  
486       nificant unitig  $u$  (defined by the *SFF*) as the set of unitigs whose shortest  
487       path to  $u$  has at most 5 edges. The objects returned by DBGWAS are the  
488       connected components of the graph induced by the neighbourhoods of all  
489       significant unitigs in the cDBG. As illustrated in Figure 5, nearby signifi-  
490       cant unitigs might belong to the same connected component, so this process  
491       groups unitigs which are likely to be located closely in the genomes. We  
492       refer to the connected components as *subgraphs* in the Results section.

493       The *SFF* value can be tuned to optimise the number and size of the out-  
494       put subgraphs (Supplementary Section 4). The *SFF* value has no impact on  
495       subgraphs mostly describing SNPs in core sequences (Supplementary Fig-  
496       ures S2). When significant unitigs map to different regions of a single MGE  
497       such as a plasmid, several subgraphs are generated but can be gathered  
498       into a single subgraph by increasing the *SFF* threshold (Supplementary  
499       Figures S4). When significant unitigs map to several distinct mobile regions  
500       which can be found in different contexts (transposon, integron, etc.) at the  
501       population level, the resulting subgraph can be huge and highly branch-  
502       ing: decreasing the *SFF* threshold allows to select the few most significant  
503       unitigs generating a subgraph focusing on the most relevant region (Supple-  
504       mentary Figure S6).

505       **Representing metadata with coloured DBGs.** The subgraphs are  
506       enriched with metadata to make their interpretation easier. We use the node  
507       size to represent allele frequencies, *i.e.*, the proportion of genomes containing  
508       the unitig sequence. We describe the effect  $\beta$  of each unitig as estimated  
509       by the LMM using colours, in the spirit of the coloured DBG (Iqbal et al.,  
510       2012). Colours are continuously interpolated between red for unitigs with a  
511       strong positive effect and blue for those with a strong negative effect.

512       **Annotating the subgraphs.** DBGWAS offers an optional annotation  
513       step using the Blast suite (Camacho et al., 2009) (version 2.6.0+) on lo-  
514       cal user-defined protein or nucleic acid sequence databases. We annotate  
515       the subgraphs of interest by blasting each unitig sequence to the available




Figure 5: **Subgraphs induced by the neighbourhood of significantly associated unitigs.** In this example, a neighbourhood of size 2 was used: any unitig distant up to 2 edges from a significant unitig is retrieved to define its neighbourhood. Neighbourhoods are merged if they share at least one node, e.g. the neighbourhoods of  $U_1$  and  $U_2$  are merged because they share  $N_6$ , and will be represented in a single subgraph.

516 databases. Users can then easily retrieve the annotations which are the most  
 517 supported by the nodes in the subgraph, or with the lowest E-value. We  
 518 provide on the DBGWAS website a resistance determinant database built by  
 519 merging the ResFinder, MEGARes, and ARG-ANNOT databases (Zankari  
 520 et al., 2012; Lakin et al., 2017; Gupta et al., 2014), and a subset of UniProt  
 521 restricted to bacterial proteins (UniProt consortium, 2017). Subgraphs dis-  
 522 cussed in the Results section were annotated using these databases.

523 **Interactive visualization.** DBGWAS produces an interactive view  
 524 of the enriched and annotated subgraphs, allowing the user to explore the  
 525 graph topology together with information on each node: allele and phe-  
 526 notype frequencies, q-value, estimated effect, and annotation. The view is  
 527 built using HTML, CSS, and several Javascript libraries, the main one be-  
 528 ing Cytoscape.js (Franz et al., 2015). Results can be shared and visualized  
 529 in a web browser. A large number of components can be produced in one  
 530 run of DBGWAS. We thus provide a summary page allowing the user to  
 531 preview and filter the subgraphs. Filtering can be based upon the minimum  
 532 q-value of all unitigs in the component ( $\min_q$ ), or based on the annotations.  
 533 A complete description of the DBGWAS interactive interface is available in  
 534 Supplementary Section 6.

535

## Datasets

536  
537  
538  
539  
540  
541  
542

We used in our experiments genome sequences from three bacterial species with various degrees of genome plasticity, from more clonal to more plastic: *Mycobacterium tuberculosis*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*. We build a fourth panel (see below WHO list panel), used only for time and memory performance assessment and defined according to the top-3 WHO priority pathogens list<sup>1</sup>. These panels are summarised in Table 2.

Table 2: **Panels used in this study.** We selected 3 bacterial species for their distinctly differing levels of genome plasticity, plus an inter-species panel integrating the top-3 WHO priority pathogens list.

Panel name	Species	Genome plasticity	Range of genome length	Source
TB	<i>M. tuberculosis</i>	very low	4.4 Mbp	(Davis et al., 2016)
SA	<i>S. aureus</i>	low	2.7-3.1 Mbp	(Gordon et al., 2014)
PA	<i>P. aeruginosa</i>	high	5.8-7.6 Mbp	(van Belkum et al., 2015)
WHO list	<i>A. baumannii</i> <i>P. aeruginosa</i> <i>K. pneumoniae</i> <i>E. coli</i> <i>Enterobacter</i> sp. <i>E. cloacae</i>	high	3.5-7.6 Mbp	PATRIC

543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555

**TB panel.** *M. tuberculosis* (TB) is a human pathogen causing 1.7 million deaths each year<sup>2</sup>. This species is known for its apparent absence of horizontal gene transfer (HGT) and accordingly, most of the reported resistance determinants are chromosomal mutations (Gygli et al., 2017) in core genes or gene promoters. Intergenic regions are also described to be instrumental in multidrug-resistance (MDR) and extensively drug-resistant (XDR) phenotypes (Zhang et al., 2013). We use the PATRIC AMR phenotype data, as well as genome assemblies from their resource (Wattam et al., 2016; Davis et al., 2016). We thus gather a total of 1302 genomes after filtering based on genome length. Phenotype data include isoniazid, rifampicin, streptomycin, ethambutol, ofloxacin, kanamycin and ethionamide resistance status. Except for the last three drugs, phenotype data are available for more than a thousand genomes. We reconstruct MDR and XDR

<sup>1</sup><http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/>

<sup>2</sup><http://www.who.int/mediacentre/factsheets/fs104/en/>

556 phenotypes based on the WHO definition<sup>3</sup>. XDR phenotype could only be  
557 defined for 689/1302 strains as it required data for at least 4 drugs. In-  
558 formation on how phenotype data and genome assemblies were obtained is  
559 available on the PATRIC website.

560 **SA panel.** *S. aureus* is a human pathogen causing life-threatening in-  
561 fections. It is subject to HGT and many plasmids, mobile elements, and  
562 phage sequences have been described in its genome. However, this does not  
563 affect the species' genome size which is always close to 3 Mbp (Mlynarczyk  
564 et al., 1998). Most antibiotic resistance mechanisms are well determined by  
565 known variants as shown in a previous study (Gordon et al., 2014). This  
566 study obtained an overall sensitivity of 97% for predicting 12 phenotypes  
567 from rules based on antibiotic marker mapping. We use this study panel of  
568 992 strains obtained by merging their derivation and validation sets.

569 **PA panel.** *P. aeruginosa* is a ubiquitous bacterial species responsible  
570 for various types of infections. It is highly adaptable thanks to its ability to  
571 exchange genetic material within the species. The species accessory genome  
572 is particularly important both in terms of size and diversity and carries more  
573 than half of the genetic determinants already described to confer resistance  
574 to antimicrobial drugs (Kung et al., 2010; van Belkum et al., 2015; Jaillard  
575 et al., 2017b). We use a panel of 282 strains, gathered from two collections  
576 which mostly include clinical strains: the bioMérieux collection (van Belkum  
577 et al., 2015) ( $n=219$ ) and the Pirnay collection (Pirnay et al., 2009) ( $n=63$ ).  
578 Genome assemblies and categorical phenotypes for 9 antibiotics are avail-  
579 able (Jaillard et al., 2017b). Binarised phenotypes of amikacin resistance  
580 are available on the DBGWAS project page to provide this dataset as an  
581 example for users.

582 **WHO list panel.** This panel is built from PATRIC AMR Phenotype  
583 data and genome resource and is designed to search for resistance determi-  
584 nants which are shared by the top-3 pathogens in the WHO priority list, all  
585 Gram negative: *Acinetobacter baumannii* carbapenem-resistant, *P. aerug-  
586 inosa* carbapenem-resistant, and Enterobacteriaceae carbapenem-resistant,  
587 ESBL-producing.

588 We collate all genomes having a phenotype for at least one of the an-  
589 tibiotics belonging to the carbapenem family (imipenem, meropenem, er-  
590 tapenem or doripenem). It represents 234 genomes with phenotype data for  
591 *A. baumannii*, 125 for *P. aeruginosa*, 135 for *K. pneumoniae*, 6 for *E. coli*,  
592 3 for *Enterobacter sp.*, and 2 for *E. cloacae*.

593 **Phenotype binarisation.** Most available phenotypes are categorical,  
594 with S, I and R levels, respectively, for susceptible, intermediary, and resis-  
595 tant. We binarise them by assigning a zero value to susceptible strains (S)  
596 and one to others (I and R).

---

<sup>3</sup><http://www.who.int/tb/areas-of-work/drug-resistant-tb>

597

## Resistome-based GWAS (RWAS)

598

RWAS are performed to validate that DBGWAS retrieves all known determinants found by a targeted approach. In this validation study we used bugwas with the same phenotypes and population structure matrix  $W$  so the RWAS analyses and DBGWAS only differ by their input variant matrix (unitigs *versus* SNPs or genes presence/absence).

603

***P. aeruginosa*.** We use the variant matrix described previously (Jaillard et al., 2017b), which includes presence/absence of known resistance genes and gene variants, as well as all SNPs called against a reference sequence of these genes (and gene variants).

607

***M. tuberculosis*.** We build the variant matrix using the same approach as for *P. aeruginosa* (Jaillard et al., 2017b): we call the SNPs from a list of known resistance genes (Coll et al., 2015; Gygli et al., 2017; Palomino and Martin, 2014) (available in Supplementary Section 3.1).

611

We sort the rows of the output file by q-values. Tables S6 and S7 summarise all top variants using their q-value ranks, while Figure 3 reports the annotations of all variant with a q-value  $< 0.05$  for *M. tuberculosis* streptomycin and *P. aeruginosa* levofloxacin resistance.

614

## Kmer-based GWAS

615

We benchmarked DBGWAS, SEER (Lees et al., 2016) and HAWK (Rahman et al., 2017) in terms of computational efficiency (running time and memory usage), simplicity of use and downstream analyses (Supplementary Section 3.2), and the ability to retrieve known markers (see Figure 3).

620

**SEER.** We installed SEER static precompiled v1.1.3. SEER's pipeline is mainly composed of four steps: 1) Kmer counting; 2) Population structure estimation; 3) Running SEER; 4) Downstream analysis. For running these steps with the correct parameters, we followed the tutorial available on SEER's github page: for kmer counting, we used fsm-lite and for step 2, we used Mash v2.0 (Ondov et al., 2016). In step 3, we used a `--maf 0.01`. Downstream analysis involved getting the kmers that were called significant by SEER, sorting them by LRT p-value, blasting them against the two databases presented in Section *step 3*, keeping the best hit for each kmer.

625

**HAWK.** We installed HAWK v0.8.3-beta. HAWK's pipeline comprises five steps: 1) Kmer counting; 2) Running HAWK; 3) Assembling significant kmers; 4) Getting statistics on the assembled sequences; 5) Downstream analysis. The first four steps were performed as described in HAWK's github page. However, in the first step, we had to remove the lower-count cutoff in `jellyfish dump` (parameter `-L`), since we are working with contigs and not reads. Moreover, for assembling the significant kmers, we used ABYSS v2.0.2 (Jackman et al., 2017). Finally, the last step was performed similarly as the one described for SEER.

630

631

632

633

634

635

636

637

## Data and source code access

All data used in this work were previously published.

Data generated by our method and discussed in the manuscript are available at [http://leoisl.gitlab.io/DBGWAS\\_support/experiments](http://leoisl.gitlab.io/DBGWAS_support/experiments).

The source code and precompiled version of our method is available on gitlab: <https://gitlab.com/leoisl/dbgwas/>.

## Acknowledgments

The authors thank Jean-Baptiste Veyrieras, Sarah Earle, Chieh-Hsi Wu and Daniel Wilson, as well as Jean-Pierre Flandrois, Manolo Gouy, Stéphane Schicklin and Ghislaine Guigon for their insightful comments. LL acknowledges CNPq/Brazil for the financial support. This work was performed using the computing facilities of the CC LBBE/PRABI. LL is funded by the Brazilian Ministry of Science, Technology and Innovation (in portuguese, Ministério da Ciência, Tecnologia e Inovação - MCTI) through the National Counsel of Technological and Scientific Development (in portuguese, Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq), under the Science Without Borders (in portuguese, Ciências Sem Fronteiras) scholarship grant process number 203362/2014-4. VL is funded by the Agence Nationale de la Recherche ANR-12-BS02-0008 (Colib'read) and ANR-16-CE23-0001 (ASTER). LJ is funded by the Agence Nationale de la Recherche ANR-14-CE23-0003-01 (MACARON) and ANR-17-CE23-0011-01 (FAST-BIG).

## Author contributions

MJ and LJ designed the method with the help of VL and MT. LL, LJ and MJ implemented the code available on gitlab. MJ, LL and PM ran the experiments described in this paper. MJ, LL, LJ, PM and AvB wrote the manuscript. All authors have reviewed and approved the final version of the manuscript.

## Disclosure declaration

MJ, MT, PM and AvB are employees of bioMérieux and hence have a business implication in all work presented here. However, the study was designed and executed in an open manner and the presented method as well as all data generated have been deposited in the public domain, also resulting in the current publication.

## References

Alam MT, Petit RA, Crispell EK, Thornton TA, Conneely KN, Jiang Y, Satola SW, and Read TD. 2014. Dissecting vancomycin-intermediate resistance in *Staphylococcus aureus* using genome-wide association. *Genome biology evolution*, **6**(5):1174–1185.

Ali-Ahmad A, Fadel F, Sebban-Kreuzer C, Ba M, Pélissier GD, Bornet O, Guerlesquin F, Bourne Y, Bordi C, and Vincent F, *et al.*. 2017. Structural and functional insights into the periplasmic detector domain of the GacS histidine kinase controlling biofilm formation in *Pseudomonas aeruginosa*. *Sci. reports*, **7**(1):11262.

Baaijens JA, El Aabidine AZ, Rivals E, and Schönhuth A. 2017. *De novo* assembly of viral quasispecies using overlap graphs. *Genome research*, **27**(5):835–848.

Balding DJ. 2006. A tutorial on statistical methods for population association studies. *Nat. reviews genetics*, **7**(10):781–791.

Benjamini Y and Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. royal statistical society. Ser. B (Methodological)*, :289–300.

Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, and Sayers EW. 2012. Genbank. *Nucleic acids research*, **41**(D1):D36–D42.

Bi D, Xie Y, Tai C, Jiang X, Zhang J, Harrison EM, Jia S, Deng Z, Rajakumar K, and Ou HY, *et al.*. 2016. A site-specific integrative plasmid found in *Pseudomonas aeruginosa* clinical isolate HS87 along with a plasmid carrying an aminoglycoside-resistant gene. *PLoS one*, **11**(2):e0148367.

Blair JM, Webber MA, Baylay AJ, Ogbolu DO, and Piddock LJ. 2015. Molecular mechanisms of antibiotic resistance. *Nat. reviews microbiology*, **13**(1):42–51.

Butler J, MacCallum I, Kleber M, Shlyakhter IA, Belmonte MK, Lander ES, Nusbaum C, and Jaffe DB. 2008. ALLPATHS: *de novo* assembly of whole-genome shotgun microreads. *Genome research*, **18**(5):810–820.

Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, and Madden TL. 2009. BLAST+: architecture and applications. *BMC bioinformatics*, **10**(1):421.

Chewapreecha C, Marttinen P, Croucher NJ, Salter SJ, Harris SR, Mather AE, Hanage WP, Goldblatt D, Nosten FH, Turner C, *et al.*. 2014. Comprehensive identification of single nucleotide polymorphisms associated with beta-lactam resistance within pneumococcal mosaic genes. *PLoS genetics*, **10**(8):e1004547.

Chikhi R, Limasset A, and Medvedev P. 2016. Compacting de Bruijn graphs from sequencing data quickly and in low memory. *Bioinforma.*, **32**(12):i201 – i208.

Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, *et al.*. 2015. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome medicine*, **7**(1):51.

Davis JJ, Boisvert S, Brettin T, Kenyon RW, Mao C, Olson R, Overbeek R, Santerre J, Shukla M, Wattam AR, *et al.* 2016. Antimicrobial resistance prediction in PATRIC and RAST. *Sci. reports*, **6**:27930.

de Bruijn N. 1946. A combinatorial problem. *Proc. koninklijke nederlandse akademie van wetenschappen. Ser. A*, **49**(7):758.

Drezen E, Rizk G, Chikhi R, Deltel C, Lemaitre C, Peterlongo P, and Lavenier D. 2014. GATB: genome assembly & analysis tool box. *Bioinforma.*, **30**(20):2959–2961.

Dunne Jr WM, Jaillard M, Rochas O, and Van Belkum A. 2017. Microbial genomics and antimicrobial susceptibility testing. *Expert. review molecular diagnostics*, **17**(3):257–269.

Earle SG, Wu CH, Charlesworth J, Stoesser N, Gordon NC, Walker TM, Spencer CC, Iqbal Z, Clifton DA, Hopkins KL, *et al.* 2016. Identifying lineage effects when controlling for population structure improves power in bacterial association studies. *Nat. microbiology*, :16041.

Falush D and Bowden R. 2006. Genome-wide association mapping in bacteria? *Trends microbiology*, **14**(8):353–355.

Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, *et al.* 2013. Genomic analysis identifies targets of convergent positive selection in drug-resistant *Mycobacterium tuberculosis*. *Nat. genetics*, **45**(10):1183–1189.

Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, *et al.* 2016. Genetic determinants of drug resistance in *Mycobacterium tuberculosis* and their diagnostic value. *Am. journal respiratory critical care medicine*, **194**(5):621–630.

Flandrois JP, Lina G, and Dumitrescu O. 2014. MUBII-TB-DB: a database of mutations associated with antibiotic resistance in *Mycobacterium tuberculosis*. *BMC bioinformatics*, **15**(1):107.

Franz M, Lopes CT, Huck G, Dong Y, Sumer O, and Bader GD. 2015. Cytoscape.js: a graph theory library for visualisation and analysis. *Bioinforma.*, **32**(2):309–311.

Gordon N, Price J, Cole K, Everitt R, Morgan M, Finney J, Kearns A, Pichon B, Young B, Wilson D, *et al.* 2014. Prediction of *Staphylococcus aureus* antimicrobial resistance by whole-genome sequencing. *J. clinical microbiology*, **52**(4):1182–1191.

Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, and Rolain JM. 2014. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. *Antimicrob. agents chemotherapy*, **58**(1):212–220.

Gygli SM, Borrell S, Trauner A, and Gagneux S. 2017. Antimicrobial resistance in *Mycobacterium tuberculosis*: mechanistic and evolutionary perspectives. *FEMS microbiology reviews*, **41**(3):354–373.

Hooper DC and Jacoby GA. 2015. Mechanisms of drug resistance: quinolone resistance. *Annals New York academy sciences*, **1354**(1):12–31.

Illakkiam D, Shankar M, Ponraj P, Rajendhran J, and Gunasekaran P. 2014. Genome sequencing of a mung bean plant growth promoting strain of *P. aeruginosa* with biocontrol ability. *Int. journal genomics*, **2014**.

Iqbal Z, Caccamo M, Turner I, Flieck P, and McVean G. 2012. *De novo* assembly and genotyping of variants using colored de bruijn graphs. *Nat. Genet.*, **44**(2):226–232.

IWG-SCC consortium . 2009. Classification of staphylococcal cassette chromosome *mec* (SCC*mec*): guidelines for reporting novel SCC*mec* elements. *Antimicrob. agents chemotherapy*, **53**(12):4961–4967.

Jackman SD, Vandervalk BP, Mohamadi H, Chu J, Yeo S, Hammond SA, Jahesh G, Khan H, Coombe L, Warren RL, *et al.*. 2017. Abyss 2.0: resource-efficient assembly of large genomes using a bloom filter. *Genome research*, **27**(5):768–777.

Jaillard M, Tournoud M, Lima L, Lacroix V, Veyrieras JB, and Jacob L. 2017a. Representing genetic determinants in bacterial GWAS with compacted De Bruijn graphs. *bioRxiv doi: 10.1101/113563*, .

Jaillard M, van Belkum A, Cady KC, Creely D, Shortridge D, Blanc B, Barbu EM, Dunne WM, Zambardi G, Enright M, *et al.*. 2017b. Correlation between phenotypic antibiotic susceptibility and the resistome in *Pseudomonas aeruginosa*. *Int. journal antimicrobial agents*, .

Kung VL, Ozer EA, and Hauser AR. 2010. The accessory genome of *Pseudomonas aeruginosa*. *Microbiol. molecular biology reviews*, **74**(4):621–641.

Lakin SM, Dean C, Noyes NR, Dettenwanger A, Ross AS, Doster E, Rovira P, Abdo Z, Jones KL, Ruiz J, *et al.*. 2017. MEGARes: an antimicrobial resistance database for high throughput sequencing. *Nucleic acids research*, **45**(D1):D574–D580.

Lambert P. 2002. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*. *J. royal society medicine*, **95**(Suppl 41):22.

Lambert T, Ploy M, and Courvalin P. 1994. A spontaneous point mutation in the *aac(6')*-*Ib*' gene results in altered substrate specificity of aminoglycoside 6'-N-acetyltransferase of a *Pseudomonas fluorescens* strain. *FEMS microbiology letters*, **115**:297–304.

Le Bras Y, Collin O, Monjeaud C, Lacroix V, Rivals É, Lemaitre C, Miele V, Sacomoto G, Marchet C, Cazaux B, *et al.*. 2016. Colib'read on galaxy: a tools suite dedicated to biological information extraction from raw NGS reads. *GigaScience*, **5**(1):1.

Lee H, Cho S, Bang H, Lee J, Bai G, Kim S, and Kim J. 2000. Exclusive mutations related to isoniazid and ethionamide resistance among *Mycobacterium tuberculosis* isolates from Korea. *The international journal tuberculosis lung disease*, **4**(5):441–447.

Lees JA, Vehkala M, Välimäki N, Harris SR, Chewapreecha C, Croucher NJ, Marttinen P, Davies MR, Steer AC, Tong SY, *et al.*. 2016. Sequence element enrichment analysis to determine the genetic basis of bacterial phenotypes. *Nat. communications*, **7**:12797.

Limasset A, Rizk G, Chikhi R, and Peterlongo P. 2017. Fast and scalable minimal perfect hashing for massive key sets. *arXiv doi:1702.03154*, .

Lowy FD. 2003. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J. clinical investigation*, **111**(9):1265.

Marschall T, Marz M, Abeel T, Dijkstra L, Dutilh BE, Ghaffaari A, Kersey P, Kloosterman WP, Mäkinen V, Novak AM, et al.. 2016. Computational pan-genomics: status, promises and challenges. *Briefings bioinformatics*, :bbw089.

Mlynarczyk A, Mlynarczyk G, and Jeljaszewicz J. 1998. The genome of *Staphylococcus aureus*: a review. *Zentralblatt für Bakteriologie*, **287**(4):277–314.

Ondov BD, Treangen TJ, Melsted P, Mallonee AB, Bergman NH, Koren S, and Phillippy AM. 2016. Mash: fast genome and metagenome distance estimation using minhash. *Genome biology*, **17**(1):132.

Palomino JC and Martin A. 2014. Drug resistance mechanisms in *Mycobacterium tuberculosis*. *Antibiot.*, **3**(3):317–340.

Paten B, Novak AM, Eizenga JM, and Garrison E. 2017. Genome graphs and the evolution of genome inference. *Genome research*, **27**(5):665–676.

Pevzner PA, Tang H, and Waterman MS. 2001. An Eulerian path approach to DNA fragment assembly. *Proc. national academy sciences*, **98**(17):9748–9753.

Pirnay JP, Bilocq F, Pot B, Cornelis P, Zizi M, Van Eldere J, Deschaght P, Vaneechoutte M, Jennes S, Pitt T, et al.. 2009. *Pseudomonas aeruginosa* population structure revisited. *PLoS one*, **4**(11):e7740.

Piton J, Petrella S, Delarue M, André-Leroux G, Jarlier V, Aubry A, and Mayer C. 2010. Structural insights into the quinolone resistance mechanism of *Mycobacterium tuberculosis* DNA gyrase. *PLoS one*, **5**(8):e12245.

Power RA, Parkhill J, and de Oliveira T. 2017. Microbial genome-wide association studies: lessons from human GWAS. *Nat. reviews genetics*, **18**(1):41–50.

Rahman A, Hallgrímsdóttir I, Eisen MB, and Pachter L. 2017. Association mapping from sequencing reads using k-mers. *bioRxiv doi: 10.1101/141267*, .

Read TD and Massey RC. 2014. Characterizing the genetic basis of bacterial phenotypes using genome-wide association studies: a new direction for bacteriology. *Genome medicine*, **6**(11):109.

Sheppard SK, Didelot X, Meric G, Torralbo A, Jolley KA, Kelly DJ, Bentley SD, Maiden MC, Parkhill J, and Falush D, et al.. 2013. Genome-wide association study identifies vitamin B5 biosynthesis as a host specificity factor in *Campylobacter*. *Proc. national academy sciences*, **110**(29):11923–11927.

Traore H, Fissette K, Bastian I, Devleeschouwer M, and Portaels F. 2000. Detection of rifampicin resistance in *Mycobacterium tuberculosis* isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. *The international journal tuberculosis lung disease*, **4**(5):481–484.

UniProt consortium . 2017. UniProt: the universal protein knowledgebase. *Nucleic acids research*, **45**(D1):D158–D169.

van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G, *et al.* 2015. Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant *Pseudomonas aeruginosa*. *mBio*, **6**(6):e01796–15.

Wattam AR, Davis JJ, Assaf R, Boisvert S, Brettin T, Bun C, Conrad N, Dietrich EM, Disz T, Gabbard JL, *et al.* 2016. Improvements to PATRIC, the all-bacterial bioinformatics database and analysis resource center. *Nucleic acids research*, **45**(D1):D535–D542.

Westh H, Hougaard D, Vuust J, and Rosdahl V. 1995. Prevalence of *erm* gene classes in erythromycin-resistant *Staphylococcus aureus* strains isolated between 1959 and 1988. *Antimicrob. agents chemotherapy*, **39**(2):369–373.

Widmer C, Lippert C, Weissbrod O, Fusi N, Kadie C, Davidson R, Listgarten J, and Heckerman D. 2014. Further improvements to linear mixed models for genome-wide association studies. *Sci. reports*, **4**.

Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, and Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J. antimicrobial chemotherapy*, **67**(11):2640–2644.

Zerbino D and Birney E. 2008. Velvet: algorithms for *de novo* short read assembly using de Bruijn graphs. *Genome research*, .

Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, *et al.* 2013. Genome sequencing of 161 *Mycobacterium tuberculosis* isolates from China identifies genes and intergenic regions associated with drug resistance. *Nat. genetics*, **45**(10):1255–1260.

Zhang W, Chen J, Yang Y, Tang Y, Shang J, and Shen B. 2011. A practical comparison of *de novo* genome assembly software tools for next-generation sequencing technologies. *PloS one*, **6**(3):e17915.

Zhou X and Stephens M. 2012. Genome-wide efficient mixed-model analysis for association studies. *Nat. genetics*, **44**(7):821–824.

Zhou X and Stephens M. 2014. Efficient multivariate linear mixed-model algorithms for genome-wide association studies. *Nat. methods*, **11**(4):407.